<DOC>
	<DOCNO>NCT00650078</DOCNO>
	<brief_summary>The purpose study compare safety efficacy , regard sign symptom , MR prednisone ( Lodotra® ) versus placebo combination standard Disease Modifying Anti-Rheumatic Drug ( DMARD ) treatment patient active rheumatoid arthritis .</brief_summary>
	<brief_title>Study Assess Safety Efficacy Modified-Release Prednisone ( Lodotra® ) Therapy Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Documented history RA agreement ACR criterion DMARD treatment RA great equal 6 month , stable dose great equal 6 week prior screen visit Duration morning stiffness great equal 45 minute great equal 4 swollen joint ( 28 ) great equal 4 tender joint ( 28 ) Suffering another disease , require glucocorticoid treatment study period Synovectomy within 4 month prior study start Use glucocorticoid : Continued use systemic glucocorticoid within 4 week prior screen visit Intermittent use glucocorticoid within 2 week prior screen visit . Joint injection within 6 week prior screen visit Topical glucocorticoid must stop screen visit Use biologicals : tumor necrosis factor α ( TNFα ) inhibitor compound within 5 serum half live prior screen visit Pregnancy nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Signs Symptoms</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Connective Tissue Diseases</keyword>
	<keyword>Arthritis , Rheumatoid</keyword>
	<keyword>Rheumatic Diseases</keyword>
	<keyword>Predniso ( lo ) ne</keyword>
</DOC>